Risk Factors for Dementia in Patients With Incident Rheumatoid Arthritis: A Population-Based Cohort Study

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.

This work was supported by grants from the National Institutes of Health (NIH), National Institute on Aging (NIA; R01 AG068192, R01 AG034676), and National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR46849). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, collection, analysis, or interpretation of data, or writing or submitting the manuscript. C. Kodishala, MBBS, DM, V.L. Kronzer, MD, MSCI, J.M. Davis III, MD, Division of Rheumatology, Mayo Clinic; C.A. Hulshizer, BA, Department of Quantitative Health Sciences, Mayo Clinic; V.K. Ramanan, MD, PhD, Department of Neurology, Mayo Clinic; M. Vassilaki, MD, PhD, Department of Quantitative Health Sciences, Mayo Clinic; M.M. Mielke, PhD, Department of Quantitative Health Sciences, Department of Neurology, Mayo Clinic; C.S. Crowson, PhD, Division of Rheumatology, Department of Quantitative Health Sciences, Mayo Clinic; E. Myasoedova, MD, PhD, Division of Rheumatology, Department of Internal Medicine, Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. JMD has received a research grant from Pfizer. MV has received research funding from F. Hoffmann-La Roche and Biogen; consultant fees from F. Hoffmann-La Roche; research funding from NIA; and has equity ownership in Abbott, Johnson and Johnson, Medtronic, and Amgen. MMM has received consultant fees from Biogen, Brain Protection Company, and LabCorp; and research funding from the NIH and Department of Defense. All other authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. E. Myasoedova, 200 First Street SW, Rochester, MN 55905, USA. Email: Myasoedova.elena@mayo.edu. Accepted for publication June 30, 2022.